While SP has invested heavily in research for evaluation of drug-induced proarrhythmia risk, new forms of CV toxicity have emerged. For instance, SP is challenged to detect and interpret more subtle forms of functional and/or structural CV effects. These new CV liabilities call for new tools for risk identification, assessment and mitigation. INSPIRE aims to extend the SP toolbox by exploring novel technologies and by turning these into new products or services for improved assessment of drug-induced CV toxicity. This way, INSPIRE will contribute to more efficiency in drug development and will protect patients from experiencing CV adverse events.
To achieve its overall mission, INSPIRE will pursue the following specific objectives:
Work Package 1: Pursuing technology innovation to enable more accurate CV risk assessment, thereby contributing to the 3 Rs. Specifically, INSPIRE will focus on i) next generation hiPSC CM assays, ii) novel strategies for in vivo and ex vivo haemodynamic evaluations, iii) mathematical modelling for in silico predictions and iv) mass spectrometry imaging (MSI).
Work Package 2: Addressing new forms of functional or structural CV toxicity issues. More specifically, INSPIRE aims to better detect and interpret i) haemodynamic effects and ii) long-term structural cardiotoxicity (e.g. cardio-oncology).
Work Package 3: Turning the prototypes developed in the first work package into validated (commercial) products/services that are ready for implementation in SP studies.
Work Package 4: Training the next generation of entrepreneurial SP scientists to have a broad view on the field.